{"id":182121,"date":"2025-09-19T09:28:05","date_gmt":"2025-09-19T08:28:05","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/"},"modified":"2025-09-19T09:28:05","modified_gmt":"2025-09-19T08:28:05","slug":"un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/","title":{"rendered":"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer"},"content":{"rendered":"<p>Un nuevo test sangu\u00edneo, desarrollado por\u00a0<a href=\"https:\/\/admit-therapeutics.com\/en\/\" target=\"_blank\">ADmit Therapeutics<\/a>, una biotecnol\u00f3gica surgida del\u00a0Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL),\u00a0permite anticipar con precisi\u00f3n qu\u00e9 personas con deterioro cognitivo leve evolucionar\u00e1n hacia una demencia de alzheimer. Es el primer biomarcador sangu\u00edneo con capacidad pron\u00f3stica y supone un avance frente a las pruebas actuales, que solo confirman la enfermedad cuando ya est\u00e1 presente.<\/p>\n<p>La validaci\u00f3n cl\u00ednica de la prueba ha sido llevada a cabo por el Hospital de Bellvitge y sus\u00a0resultados se han publicado en la revista iScience (Cell Press). Seg\u00fan un comunicado de IDIBELL, el test ha obtenido ya el marcado CE-IVDR, que certifica su seguridad y eficacia en la Uni\u00f3n Europea y allana el camino para su uso cl\u00ednico.<\/p>\n<p>El test ha obtenido ya el marcado CE-IVDR de la UE, que certifica su seguridad y eficacia y allana el camino para su uso cl\u00ednico<\/p>\n<p>En Catalu\u00f1a, un 2% de la poblaci\u00f3n convive con alg\u00fan tipo de demencia, y el alzh\u00e9imer representa cerca del 70% de los casos, seg\u00fan datos del CatSalut. La prevalencia aumenta con la edad y alcanza al 9,6 % de los mayores de 70 a\u00f1os.<\/p>\n<p>La presentaci\u00f3n de este avance coincide con la jornada Nuevos tiempos, nuevas respuestas, organizada en el Hospital de Bellvitge con motivo del D\u00eda Mundial del Alzheimer, que se celebra el 21 de septiembre.<\/p>\n<p><a><\/a><\/p>\n<h2>Muestras de pacientes<\/h2>\n<p>Para validar el biomarcador se han analizado muestras de pacientes con deterioro cognitivo leve y de voluntarios sanos, procedentes de hospitales como el Cl\u00ednic de Barcelona, el de la Santa Creu i Sant Pau y la Fundaci\u00f3n CITA-Alzheimer, adem\u00e1s de biobancos de la Universidad de Washington y el Australian Imaging, Biomarker and Lifestyle Study.<\/p>\n<p>El test MAP-AD\u00ae combina la medici\u00f3n de biomarcadores mitocondriales \u2014la\u00a0metilaci\u00f3n del ADN mitocondrial\u2014 con datos cl\u00ednicos, lo que permite predecir con alta fiabilidad qu\u00e9 pacientes progresar\u00e1n a demencia y cu\u00e1les permanecer\u00e1n estables.<\/p>\n<p>MAP-AD\u00ae predice con alta fiabilidad la progresi\u00f3n a demencia combinando biomarcadores mitocondriales y datos cl\u00ednicos.<\/p>\n<p>\u201cDurante a\u00f1os hemos podido identificar la patolog\u00eda subyacente, pero era muy dif\u00edcil predecir la evoluci\u00f3n cl\u00ednica. Disponer de una herramienta fiable que anticipe la progresi\u00f3n es un punto de inflexi\u00f3n: nos permite mantener conversaciones m\u00e1s informadas con las familias y guiar mejor las intervenciones, ya sean preventivas, en ensayos cl\u00ednicos o con nuevas terapias emergentes\u201d, explica\u00a0Jordi Gasc\u00f3n, coordinador del ensayo y\u00a0jefe de la Unidad de Memoria de Neurolog\u00eda del Hospital de Bellvitge.<\/p>\n<p>Seg\u00fan indica Marta Barrachina, consejera delegada y cofundadora de ADmit Therapeutics, destaca: \u201cA\u00a0diferencia de otros biomarcadores que solo confirman patolog\u00eda, MAP-AD\u00ae anticipa la evoluci\u00f3n cl\u00ednica. Esto lo hace \u00fanico y abre una nueva v\u00eda para mejorar la atenci\u00f3n a las personas con riesgo de padecer alzh\u00e9imer\u201d.<\/p>\n<p><a><\/a><\/p>\n<h2>Atenci\u00f3n a pacientes con deterioro cognitivo<\/h2>\n<p>El desarrollo de este biomarcador coincide con la puesta en marcha de la nueva Unidad de Memoria del Hospital de Bellvitge, que ha transformado la atenci\u00f3n a pacientes con deterioro cognitivo. El modelo integral y multidisciplinar ha reducido el tiempo de espera para la primera visita de un a\u00f1o a solo 15 d\u00edas, y ya atiende a m\u00e1s de 2.000 personas al a\u00f1o del \u00e1rea sur de L\u2019Hospitalet y El Prat de Llobregat.<\/p>\n<p>En una sola ma\u00f1ana, los pacientes reciben valoraciones m\u00e9dicas, neuropsicol\u00f3gicas, de enfermer\u00eda y de trabajo social, lo que mejora su experiencia y la de sus cuidadores. La unidad tambi\u00e9n impulsa aplicaciones digitales, programas de apoyo a cuidadores y nuevas l\u00edneas de investigaci\u00f3n. \u201cEs un proyecto que mejora la calidad de vida de pacientes y cuidadores y establece una base s\u00f3lida para el trabajo en red\u201d, concluye Gasc\u00f3n.<\/p>\n<p>Referencia: <\/p>\n<p>Gascon-Bayarri, J. et al \u201cMitochondrial methylcytosines as blood-based biomarkers for Alzheimer\u2019s disease dementia\u201d. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589004225016797?via%3Dihub\" target=\"_blank\">iScience<\/a>, 2025.<\/p>","protected":false},"excerpt":{"rendered":"<p>Un nuevo test sangu\u00edneo, desarrollado por\u00a0ADmit Therapeutics, una biotecnol\u00f3gica surgida del\u00a0Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL),\u00a0permite anticipar con precisi\u00f3n qu\u00e9 personas con deterioro cognitivo leve evolucionar\u00e1n hacia una demencia de alzheimer. Es el primer biomarcador sangu\u00edneo con capacidad pron\u00f3stica y supone un avance frente a las pruebas actuales, que solo confirman la enfermedad cuando [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-182121","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer\" \/>\n<meta property=\"og:description\" content=\"Un nuevo test sangu\u00edneo, desarrollado por\u00a0ADmit Therapeutics, una biotecnol\u00f3gica surgida del\u00a0Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL),\u00a0permite anticipar con precisi\u00f3n qu\u00e9 personas con deterioro cognitivo leve evolucionar\u00e1n hacia una demencia de alzheimer. Es el primer biomarcador sangu\u00edneo con capacidad pron\u00f3stica y supone un avance frente a las pruebas actuales, que solo confirman la enfermedad cuando [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-19T08:28:05+00:00\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer\",\"datePublished\":\"2025-09-19T08:28:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/\"},\"wordCount\":684,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/\",\"name\":\"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"datePublished\":\"2025-09-19T08:28:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/","og_locale":"es_ES","og_type":"article","og_title":"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer","og_description":"Un nuevo test sangu\u00edneo, desarrollado por\u00a0ADmit Therapeutics, una biotecnol\u00f3gica surgida del\u00a0Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL),\u00a0permite anticipar con precisi\u00f3n qu\u00e9 personas con deterioro cognitivo leve evolucionar\u00e1n hacia una demencia de alzheimer. Es el primer biomarcador sangu\u00edneo con capacidad pron\u00f3stica y supone un avance frente a las pruebas actuales, que solo confirman la enfermedad cuando [&hellip;]","og_url":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/","og_site_name":"bip4ex","article_published_time":"2025-09-19T08:28:05+00:00","author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer","datePublished":"2025-09-19T08:28:05+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/"},"wordCount":684,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/","url":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/","name":"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"datePublished":"2025-09-19T08:28:05+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/un-biomarcador-en-sangre-predice-que-pacientes-con-deterioro-cognitivo-leve-desarrollaran-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Un biomarcador en sangre predice qu\u00e9 pacientes con deterioro cognitivo leve desarrollar\u00e1n alzh\u00e9imer"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/182121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=182121"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/182121\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=182121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=182121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=182121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}